Apyx Medical Corp. (APYX) Tops Q2 EPS by 7c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Apyx Medical Corporation Reports Second Quarter 2020 Financial Results
August 10, 2020 7:00 AM EDTCLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2020.
Second Quarter 2020 Financial Summary:
Total revenue of $4.3 million, down 35% year-over-year. Advanced Energy revenue of $2.9 million, down 46% year-over-year. OEM revenue of $1.4 million, up 10%... More